Get the Stockscreener App
12.61
7.96%
0.93
After Hours:
12.61
Polyrizon Ltd stock is traded at $12.61, with a volume of 43,715.
It is up +7.96% in the last 24 hours and up +0.96% over the past month.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
See More
Previous Close:
$11.68
Open:
$12.195
24h Volume:
43,715
Relative Volume:
0.55
Market Cap:
$20.46M
Revenue:
-
Net Income/Loss:
$-3.34M
P/E Ratio:
-4.6712
EPS:
-2.6995
Net Cash Flow:
$-10.54M
1W Performance:
-11.38%
1M Performance:
+0.96%
6M Performance:
+92.81%
1Y Performance:
-97.69%
1-Day Range:
$11.40
$12.99
1-Week Range:
$10.67
$14.25
52-Week Range:
$2.88
$2,235.00
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
12.61 | 18.95M | 0 | -3.34M | -10.54M | -2.6995 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.86 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Polyrizon Ltd Stock (PLRZ) Latest News
Polyrizon (PLRZ) CEO sells 500 shares in open-market trade - Stock Titan
Carmel Liron of Polyrizon (PLRZ) sells 942 shares, holds 3,127 - Stock Titan
Polyrizon (PLRZ) director sells 3,292 shares, retains 19,850 total - Stock Titan
Patterns Watch: Can Polyrizon Ltd beat the S P 500Entry Point & Expert Curated Trade Ideas - baoquankhu1.vn
Top Polyrizon Insiders Quietly Cash Out in Notable Stock Moves - TipRanks
Director at Polyrizon (PLRZ) sells 100 shares, retains 4,069 - Stock Titan
Polyrizon (PLRZ) CEO sells 3,900 shares, holding 32,012 afterward - Stock Titan
Polyrizon (PLRZ) CTO trims stake with 2,917-share open-market sale - Stock Titan
VIX Spike: Can Polyrizon Ltd disrupt its industryGDP Growth & Growth Focused Entry Reports - baoquankhu1.vn
We're Keeping An Eye On Polyrizon's (NASDAQ:PLRZ) Cash Burn Rate - simplywall.st
US Market Wrap: Will Polyrizon Ltd outperform its industry peersWeekly Trend Recap & Risk Managed Investment Signals - baoquankhu1.vn
Polyrizon (PLRZ) updates 20-F, outlines $464,000 cyber fraud response - Stock Titan
Polyrizon reports $17.5M cash position, advances FDA discussions By Investing.com - Investing.com South Africa
Polyrizon reports $17.5M cash position, advances FDA discussions - Investing.com
Polyrizon Provides 2025 and Recent Highlights - manilatimes.net
Polyrizon pushes allergy and viral nasal blockers toward U.S. trials - Stock Titan
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 - The Manila Times
Polyrizon (PLRZ) 20-F: deepening losses, cash position and high biotech risks - Stock Titan
Polyrizon signs MOU to acquire 20% stake in drone maker Colugo - Investing.com Australia
Polyrizon signs MOU to acquire up to 20% stake in eVTOL firm Colugo - msn.com
Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications - manilatimes.net
Why a nasal drug developer wants a stake in an Israeli eVTOL drone maker - Stock Titan
Insider Sell: Does Polyrizon Ltd offer margin of safety2026 Valuation Update & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Market Trends: Will Polyrizon Ltd stock hit new highs in YEAR2026 Buyback Activity & Stepwise Trade Execution Plans - baoquankhu1.vn
Polyrizon (PLRZ) CTO details initial share and option holdings - Stock Titan
[Form 3] Polyrizon Ltd. Initial Statement of Beneficial Ownership - Stock Titan
Polyrizon (PLRZ) Chief Science Officer reports share and option holdings - Stock Titan
Director Itzhaik Asaf details restricted share holdings at Polyrizon (PLRZ) - Stock Titan
Polyrizon (PLRZ) director discloses initial restricted share holdings - Stock Titan
Polyrizon (PLRZ) director discloses vested and restricted share holdings - Stock Titan
Carmel Liron details Polyrizon (PLRZ) restricted share ownership and vesting - Stock Titan
Polyrizon (PLRZ) CEO Tomer Izraeli details initial share and option holdings - Stock Titan
Polyrizon (PLRZ) CFO details initial share and option holdings - Stock Titan
Polyrizon signs CRO agreement for biocompatibility studies By Investing.com - in.investing.com
Polyrizon signs CRO agreement for biocompatibility studies - Investing.com
Polyrizon Taps Global CRO to Run Key Preclinical Safety Studies Ahead of First Clinical Trials - TipRanks
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program - The Manila Times
Polyrizon (PLRZ) signs global CRO pact to advance nasal hydrogel trials - Stock Titan
Nasal allergy startup Polyrizon readies human trials with safety tests - Stock Titan
Eli Zamir reports ≤5% stake in Polyrizon Ltd. (PLRZ) via Schedule 13G - Stock Titan
Polyrizon (PLRZ) Institutional Ownership 2026 - MarketBeat
Polyrizon Announces GMP Manufacturing of Clinical Trial Material with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study - marketscreener.com
Polyrizon completes GMP batch for intranasal product trial By Investing.com - Investing.com South Africa
Aug Intraday: Does Polyrizon Ltd have strong fundamentalsRate Hike & AI Optimized Trade Strategies - baoquankhu1.vn
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study - Bitget
Polyrizon completes GMP batch for intranasal product trial - Investing.com India
Polyrizon Completes GMP Clinical Material for Planned U.S. Intranasal Study - TipRanks
Polyrizon (Nasdaq: PLRZ) makes GMP CTM for planned U.S. study - Stock Titan
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO ... - Caledonian Record
Polyrizon makes GMP batch for planned U.S. nasal allergy, virus trial - Stock Titan
PLRZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Polyrizon Ltd Stock (PLRZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):